Blue vs white light for transurethral resection of non-muscle-invasive bladder cancer: an abridged Cochrane Review

原文： 2022 年发布于 Front Immunol 48 卷第 7 期 S51-S52  浏览量：242次

作者： Maisch P. Koziarz A. Vajgrt J. Narayan V. Kim M. H. Dahm P.

作者单位： Epidemiology and Statistics, School of Public Health, Jilin University, Changchun, 130021, China. Department Radiology, The 2nd Hospital Affiliated to Jilin University, Changchun, China. School of Mathematics and Statistics, Northeast Normal University, Changchun, Jilin, China. Epidemiology and Statistics, School of Public Health, Jilin University, Changchun, 130021, China. liuxin2015722010@163.com.

归属分类：膀胱肿瘤治疗及预后证据

DOI： 10.13201/j.issn.1001-1420.2019.10.002

关键词： Humans Magnetic Resonance Imaging *Multiparametric Magnetic Resonance Imaging Muscles Prospective Studies Urinary Bladder *Urinary Bladder Neoplasms/diagnostic imaging Bladder cancer Meta-analysis Muscle invasion Vesical imaging-reporting and data system

Background: The incidence rate and mortality of bladder cancer are increasing year by year. Interestingly, the commonly used metabolic regulatory drug metformin has been reported to have anti-tumor effect in recent years. Nevertheless, it keeps unclear whether the usage of metformin is beneficial or unbeneficial in treating bladder cancer. Thus, a meta-analysis was conducted to explore the long-term effect of metformin on the incidence of bladder cancer and OS, PFS, DSS and RFS in bladder cancer patients with T2DM. Method: We aim to collect evidence of the association between the usage of metformin and the incidence and treatment outcome of bladder cancer. We searched PubMed, Embase, Ovid Medline and Cochrane Library up to February 2021 to get effective literature reporting the effects of metformin in bladder cancer. The main outcomes were the protective effects of metformin on the incidence, overall survival (OS), recurrence-free survival (RFS), progression-free survival (PFS), and disease-specific survival (DSS) of bladder cancer. And OR (odds ratio) and HR (hazard ratio) with their 95%CI were pooled. Two independent researchers assessed the quality of included studies using the Newcastle-Ottawa Scale (NOS). Results: We involved 12 studies meeting the inclusion criteria, including a total of 1,552,773 patients. The meta-analysis showed that use of metformin could decrease the incidence (OR = 0.45, 95%CI = 0.37-0.56; p < 0.01) and prolong recurrence-free-survival (HR = 0.56, 95%CI = 0.41-0.76; p = 0.91) of bladder cancer. However, there were no significant protective effects in the overall survival (HR = 0.93, 95%CI = 0.67-1.28, p = 0.05), disease-specific-survival (HR = 0.73, 95%CI = 0.47-1.16; p = 0.01), and progression-free-survival (HR = 0.78, 95%CI = 0.53-1.15, p = 0.34). Conclusion: The results revealed that the usage of metformin could reduce the incidence of bladder cancer and prolong the prognosis of bladder cancer in T2DM patients, respectively. More prospective studies are needed to prove the protective role of metformin on bladder cancer.